Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 54

Related Articles by Review for PubMed (Select 16186518)

1.

Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis.

Rog DJ, Nurmikko TJ, Friede T, Young CA.

Neurology. 2005 Sep 27;65(6):812-9.

PMID:
16186518
2.
3.
4.

Combined cannabinoid therapy via an oromucosal spray.

Perez J.

Drugs Today (Barc). 2006 Aug;42(8):495-503. Review.

PMID:
16969427
5.

Cannabis, pain, and sleep: lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine.

Russo EB, Guy GW, Robson PJ.

Chem Biodivers. 2007 Aug;4(8):1729-43. Review.

PMID:
17712817
6.

Systematic review and meta-analysis of cannabis treatment for chronic pain.

Martín-Sánchez E, Furukawa TA, Taylor J, Martin JL.

Pain Med. 2009 Nov;10(8):1353-68. doi: 10.1111/j.1526-4637.2009.00703.x. Epub 2009 Sep 1. Review.

PMID:
19732371
7.

Duloxetine: a review of its use in the treatment of generalized anxiety disorder.

Carter NJ, McCormack PL.

CNS Drugs. 2009;23(6):523-41. doi: 10.2165/00023210-200923060-00006. Review.

PMID:
19480470
8.
9.

[Cannabinoids in multiple sclerosis -- therapeutically reasonable?].

Trebst C, Stangel M.

Fortschr Neurol Psychiatr. 2005 Aug;73(8):463-9. Review. German.

PMID:
16052440
10.

Pharmacological management of pain in patients with multiple sclerosis.

Solaro C, Messmer Uccelli M.

Drugs. 2010 Jul 9;70(10):1245-54. doi: 10.2165/11537930-000000000-00000. Review.

PMID:
20568832
11.

Towards cannabis and cannabinoid treatment of multiple sclerosis.

Croxford JL, Miller SD.

Drugs Today (Barc). 2004 Aug;40(8):663-76. Review.

PMID:
15510238
12.

THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis.

Sastre-Garriga J, Vila C, Clissold S, Montalban X.

Expert Rev Neurother. 2011 May;11(5):627-37. doi: 10.1586/ern.11.47. Epub 2011 Apr 1. Review.

PMID:
21456949
13.

Multiple sclerosis-related central pain disorders.

Nurmikko TJ, Gupta S, Maclver K.

Curr Pain Headache Rep. 2010 Jun;14(3):189-95. doi: 10.1007/s11916-010-0108-8. Review.

PMID:
20425191
14.

Cannabis in palliative medicine: improving care and reducing opioid-related morbidity.

Carter GT, Flanagan AM, Earleywine M, Abrams DI, Aggarwal SK, Grinspoon L.

Am J Hosp Palliat Care. 2011 Aug;28(5):297-303. doi: 10.1177/1049909111402318. Epub 2011 Mar 28. Review.

PMID:
21444324
15.

Recent developments in the therapeutic potential of cannabinoids.

Corey S.

P R Health Sci J. 2005 Mar;24(1):19-26. Review.

PMID:
15895873
16.

The safety of cannabinoids for the treatment of multiple sclerosis.

Smith PF.

Expert Opin Drug Saf. 2005 May;4(3):443-56. Review.

PMID:
15934852
17.

Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review.

Lakhan SE, Rowland M.

BMC Neurol. 2009 Dec 4;9:59. doi: 10.1186/1471-2377-9-59. Review.

18.

Abuse potential and psychoactive effects of δ-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine.

Robson P.

Expert Opin Drug Saf. 2011 Sep;10(5):675-85. doi: 10.1517/14740338.2011.575778. Epub 2011 May 4. Review.

PMID:
21542664
19.

Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice.

Pozzilli C.

Expert Rev Neurother. 2013 Dec;13(12 Suppl):49-54. doi: 10.1586/14737175.2013.865877. Review.

PMID:
24289844
20.

[Cannabinoids in multiple sclerosis. Opportunity or hazard?].

Neuhaus O, Kieseier BC, Klimke A, Gaebel W, Hohlfeld R, Hartung HP.

Nervenarzt. 2004 Oct;75(10):1022-6. Review. German.

PMID:
15156287
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk